Animals were divided into four groups, each consisting of six animals and treated as follows, Group I: ischemic control (normal saline 10 ml/kg, orally), BCCA occlusion, Group II: Eclipta alba (250 mg/kg, orally) + BCCA occlusion, Group Eclipta alba (500 mg/kg, orally) + BCCA occlusion, and Group IV: Quercetin (20 mg/kg, i.
Effects of Eclipta alba on MDA content and antioxidant enzyme activities
The effects of Eclipta alba on brain MDA content, SOD, GPx, GSH, CAT, GST, and GR activities in BCA occlusion-reperfusion rats are shown in Table 1.
Table 1 Effect of hydroalcoholic extract of Eclipta alba on BCCAO, followed by 4 h reperfusion induced ischema in rats.
However, there was significant decrease of brain water content (edema) observed in Eclipta alba and Quercetin treated groups.
Eclipta alba pretreated group at 250 and 500 mg/kg tended to reduce the brain damage 11.
This effect was attenuated by administration of Eclipta alba (500 mg/kg) and Quercetin treated rats.
In the present study, the pretreatment of hydroalcoholic extract of Eclipta alba were evaluated after global cerebral ischemia, and they were found to be great difference in ischemia control and treated rats.
Our result showed that pretreatment with Eclipta alba significantly decreased the brain MDA level in dose dependant manner.
Eclipta alba extract pretreatment was found to elevate the activity of SOD in ischemic brain.
Our study indicated that pretreatment of Eclipta alba significantly elevated brain GPx level.
The dose of 250 mg/kg of Eclipta alba was ineffective to alters the CAT levels in ischemic brain, this may be explained by insufficient concentration and antioxidative capacity to defend adequately against oxygen free radicals generated in brain during ischemia.